Page last updated: 2024-11-13

rb 150

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

firibastat: has antihypertensive activity; a dimer of EC33 with a disulfide linkage; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID24851355
CHEMBL ID4297511
SCHEMBL ID1694944
MeSH IDM0521044

Synonyms (30)

Synonym
648927-86-0
firibastat
AKOS022180293
SCHEMBL1694944
rb-150
firibastat [inn]
638KY4573I ,
qgc-001
qgc001
firibastat [who-dd]
(3s,3s')-4,4'-disulfanediylbis(3-aminobutane-1-sulfonic acid)
1-butanesulfonic acid, 4,4'-dithiobis(3-amino-, (3s,3's)-
qgc 001
(3s,3's)-4,4'-dithiobis(3-aminobutane-1-sulfonic acid)
4,4'-dithio(bis(3-aminobutyl sulfonic acid))
unii-638ky4573i
rb 150
rb150
CS-0032985
HY-109058
DB13107
(s)-3-amino-4-(((s)-2-amino-4-sulfobutyl)disulfaneyl)butane-1-sulfonic acid
qgc001;rb150
1601301-49-8
Q27263587
CHEMBL4297511
MS-25919
(3s,3's)-4,4'-disulfanediylbis(3-aminobutane-1-sulfonicacid)
GLXC-25368
(3s)-3-amino-4-[[(2s)-2-amino-4-sulfobutyl]disulfanyl]butane-1-sulfonic acid

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"We conducted a pilot multicenter double-blind randomized placebo-controlled crossover pharmacodynamic study to evaluate the blood pressure (BP) and the hormonal effects of firibastat, a first-in-class aminopeptidase A inhibitor prodrug, in patients with hypertension."( A pilot double-blind randomized placebo-controlled crossover pharmacodynamic study of the centrally active aminopeptidase A inhibitor, firibastat, in hypertension.
Amar, L; Azizi, M; Balavoine, F; Courand, PY; De Mota, N; Delsart, P; Denolle, T; Lantelme, P; Llorens-Cortes, C; Mounier-Vehier, C; Zhygalina, V, 2019
)
0.51

Compound-Compound Interactions

ExcerptReferenceRelevance
" In this study, we evaluated the efficacy of firibastat in combination with enalapril, an angiotensin I-converting enzyme inhibitor, and hydrochlorothiazide (HCTZ), in conscious hypertensive deoxycorticosterone acetate (DOCA)-salt rats, which display high plasma arginine-vasopressin levels, low circulating renin levels and resistance to treatment by systemic RAS blockers."( Effects of firibastat in combination with enalapril and hydrochlorothiazide on blood pressure and vasopressin release in hypertensive DOCA-salt rats.
Balavoine, F; De Mota, N; Hmazzou, R; Llorens-Cortes, C; Marc, Y, 2021
)
0.62

Bioavailability

ExcerptReferenceRelevance
" Oral administration of RB150 in conscious DOCA-salt rats inhibited brain aminopeptidase A activity, resulting in values similar to those obtained with the brains of normotensive rats, demonstrating the central bioavailability of RB150."( Orally active aminopeptidase A inhibitors reduce blood pressure: a new strategy for treating hypertension.
Balavoine, F; Bodineau, L; Fassot, C; Frugière, A; Inguimbert, N; Llorens-Cortes, C; Marc, Y; Roques, B, 2008
)
0.35
" Oral administration of RB150 in conscious spontaneously hypertensive rats inhibited brain aminopeptidase A activity, demonstrating the central bioavailability of RB150 and its ability to generate EC33 into the brain."( Central antihypertensive effects of orally active aminopeptidase A inhibitors in spontaneously hypertensive rats.
Balavoine, F; Gao, J; Llorens-Cortes, C; Marc, Y; Michaud, A; Roques, BP, 2012
)
0.38
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (17)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (11.76)29.6817
2010's8 (47.06)24.3611
2020's7 (41.18)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 64.41

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index64.41 (24.57)
Research Supply Index3.04 (2.92)
Research Growth Index5.29 (4.65)
Search Engine Demand Index102.75 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (64.41)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (11.11%)5.53%
Reviews7 (38.89%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (50.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]